海特生物(300683) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥156,670,309, representing an increase of 18.79% compared to ¥131,887,548 in the same period last year[5] - The net loss attributable to shareholders was ¥13,930,370, a 15.81% improvement from a loss of ¥16,545,525 in the previous year[5] - The net profit for the current period was a loss of ¥14,417,854.71, an improvement compared to a loss of ¥17,491,671.96 in the previous period, indicating a reduction in losses of approximately 17.5%[24] - Basic earnings per share for the current period was -¥0.11, compared to -¥0.13 in the previous period, showing an improvement in earnings per share[25] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥49,792,802, a significant decline of 644.52% compared to a positive cash flow of ¥9,144,316 in the same period last year[5] - Operating cash flow for the period was -$49.79 million, a significant decrease from $9.14 million in the previous period, indicating a decline in operational efficiency[26] - The ending cash and cash equivalents balance was $160.74 million, down from $463.24 million, highlighting a significant liquidity reduction[27] - Total cash inflow from operating activities was $124.15 million, a decrease from $189.81 million, reflecting challenges in core business operations[26] Assets and Liabilities - The total assets decreased by 3.94% to ¥2,821,065,437 from ¥2,936,633,525 at the end of the previous year[5] - The total current assets decreased from ¥1,306,333,167.96 to ¥1,198,932,206.75, a reduction of about 8.3%[20] - The company's cash and cash equivalents decreased from ¥419,151,366.14 to ¥160,772,770.92, a decline of approximately 61.7%[20] - Total liabilities decreased to ¥423,896,092.27 from ¥525,046,325.88, a reduction of approximately 19.3%[22] Operating Costs and Expenses - Total operating costs decreased to ¥172,864,987.49 from ¥185,592,842.22, a reduction of about 6.2%[23] - The management expenses decreased by 51.71% to ¥23,870,424.25, primarily due to changes in inventory write-offs from the previous year[9] - Research and development expenses for the current period were ¥27,012,145.01, slightly down from ¥27,937,527.55 in the previous period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,175[12] - The largest shareholder, Wuhan Sanjiangyuan Investment Development Co., Ltd., holds 25,209,424 shares, accounting for 19.26% of total shares[12] - The total number of shares held by the top 10 shareholders includes significant stakes from both institutional and individual investors, with the top two shareholders holding a combined 30.56%[12] Investment and Financing Activities - Cash inflow from investment activities totaled $200.92 million, up from $173.42 million in the previous period, reflecting increased investment recovery[27] - Cash outflow for investments reached $389.20 million, compared to $224.68 million previously, indicating a substantial increase in capital expenditures[27] - Net cash flow from financing activities was -$20.30 million, worsening from -$4.80 million in the prior period, suggesting increased financial strain[27] Other Notable Points - The company reported a government subsidy of ¥2,050,978.94, contributing to its non-recurring gains[6] - The company experienced a 1063.38% increase in other operating income, reaching ¥43,579.07, attributed to a rise in non-recurring income[9] - The company has not disclosed any new product developments or market expansion strategies in the current reporting period[16] - The company did not undergo an audit for the first quarter report, which may affect stakeholder confidence in financial reporting[28]